Key clinical point: In patients with lymphoma undergoing chemotherapy, high neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) ratios appear to predict risk of thromboembolism.
Major finding: A neutrophil to lymphocyte ratio of 3.1 or more was associated with a relative risk of thromboembolism of 4.1 (P less than .001).
Study details: A retrospective study involving 484 patients with lymphoma who had undergone at least one cycle of chemotherapy.
Disclosures: The investigators reported no financial disclosures.
Otasevic V et al. EHA Congress, Abstract S1645.